Cereno Scientific is a biotech company developing treatments for the number one killer in the world - cardiovascular disease. The company has been granted the approval from EMA to initiate a first-in-human phase I trial with candidate CS014 - a novel epigenetic HDAC inhibitor. Cereno’s CEO Sten R Sörensen stopped by the BioStock Studio to share more details about the news.
0:00 Intro
0:32 What is CS014?
1:35 The promise of epigenetic modulation in cardiovascular disease
3:26 CS014 vs CS1
5:09 Next steps before clinical trial start
7:36 Significance of having more than one clinical candidate
09:43 Indication potential for CS014
12:00 Upcoming milestones for Cereno
Subscribe and follow BioStock on:
KZitem bit.ly/Biostock
LinkedIn: / biostock
Facebook: / biostock.se
www.biostock.se/
#BioStock #LifeScience #CerenoScientific
About BioStock
BioStock is Scandinavia's leading digital news and analysis service with an exclusive focus on the Life Science sector. Our primary editorial office and tv-studio is found at Medicon Village in Lund, one of Sweden's foremost innovation clusters for life science companies
Негізгі бет Cereno Scientific brings novel cardiovascular disease candidate to the clinic
No video
Пікірлер